AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease.


Journal

Metabolism: clinical and experimental
ISSN: 1532-8600
Titre abrégé: Metabolism
Pays: United States
ID NLM: 0375267

Informations de publication

Date de publication:
10 2019
Historique:
received: 10 05 2019
revised: 28 06 2019
accepted: 18 07 2019
pubmed: 23 7 2019
medline: 20 2 2020
entrez: 23 7 2019
Statut: ppublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. Steroid hormones and bile acids are potent regulators of hepatic carbohydrate and lipid metabolism. Steroid 5β-reductase (AKR1D1) is highly expressed in human liver where it inactivates steroid hormones and catalyzes a fundamental step in bile acid synthesis. Human liver biopsies were obtained from 34 obese patients and AKR1D1 mRNA expression levels were measured using qPCR. Genetic manipulation of AKR1D1 was performed in human HepG2 and Huh7 liver cell lines. Metabolic assessments were made using transcriptome analysis, western blotting, mass spectrometry, clinical biochemistry, and enzyme immunoassays. In human liver biopsies, AKR1D1 expression decreased with advancing steatosis, fibrosis and inflammation. Expression was decreased in patients with type 2 diabetes. In human liver cell lines, AKR1D1 knockdown decreased primary bile acid biosynthesis and steroid hormone clearance. RNA-sequencing identified disruption of key metabolic pathways, including insulin action and fatty acid metabolism. AKR1D1 knockdown increased hepatocyte triglyceride accumulation, insulin sensitivity, and glycogen synthesis, through increased de novo lipogenesis and decreased β-oxidation, fueling hepatocyte inflammation. Pharmacological manipulation of bile acid receptor activation prevented the induction of lipogenic and carbohydrate genes, suggesting that the observed metabolic phenotype is driven through bile acid rather than steroid hormone availability. Genetic manipulation of AKR1D1 regulates the metabolic phenotype of human hepatoma cell lines, driving steatosis and inflammation. Taken together, the observation that AKR1D1 mRNA is down-regulated with advancing NAFLD suggests that it may have a crucial role in the pathogenesis and progression of the disease.

Identifiants

pubmed: 31330134
pii: S0026-0495(19)30144-1
doi: 10.1016/j.metabol.2019.153947
pmc: PMC6744372
pii:
doi:

Substances chimiques

Bile Acids and Salts 0
RNA, Messenger 0
Oxidoreductases EC 1.-
3-oxo-5 beta-steroid delta 4-dehydrogenase EC 1.3.99.6

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

67-80

Subventions

Organisme : British Heart Foundation
ID : FS/15/56/31645
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U142661184
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P011462/1
Pays : United Kingdom
Organisme : NIEHS NIH HHS
ID : P30 ES013508
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

PLoS Med. 2018 Mar 28;15(3):e1002542
pubmed: 29590099
J Biol Chem. 2003 Oct 3;278(40):39124-32
pubmed: 12865425
J Lipid Res. 2010 Apr;51(4):771-84
pubmed: 19783811
J Pharmacol Exp Ther. 2009 Jan;328(1):116-22
pubmed: 18948497
Hepatology. 2014 Feb;59(2):471-82
pubmed: 23913408
Alcohol Clin Exp Res. 2010 Feb;34 Suppl 1:S18-24
pubmed: 18986378
Mol Cell Biol. 2001 May;21(9):2991-3000
pubmed: 11287605
World J Gastroenterol. 2013 Oct 28;19(40):6735-43
pubmed: 24187449
J Clin Endocrinol Metab. 2016 Jan;101(1):103-13
pubmed: 26574953
Trends Pharmacol Sci. 2009 Nov;30(11):570-80
pubmed: 19758712
BMC Biotechnol. 2013 Nov 20;13:104
pubmed: 24256843
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Hepatol Int. 2010 Aug 12;4(4):741-8
pubmed: 21286345
Dig Dis Sci. 2014 Dec;59(12):2975-82
pubmed: 25102981
J Hepatol. 2016 May;64(5):1158-1166
pubmed: 26812075
FASEB J. 2012 Jul;26(7):3021-31
pubmed: 22447981
Science. 2001 Mar 30;291(5513):2613-6
pubmed: 11283375
Nature. 1996 Oct 24;383(6602):728-31
pubmed: 8878485
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
Am J Physiol Endocrinol Metab. 2015 Jan 1;308(1):E1-20
pubmed: 25352434
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
J Hepatol. 2013 May;58(5):984-92
pubmed: 23333450
J Biol Chem. 2006 Apr 21;281(16):11039-49
pubmed: 16446356
J Clin Endocrinol Metab. 2003 Oct;88(10):4924-31
pubmed: 14557475
Dig Dis Sci. 2016 May;61(5):1294-303
pubmed: 26841783
Acta Med Acad Sci Hung. 1974;31(1-2):47-9
pubmed: 4464748
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hepatology. 2008 Nov;48(5):1632-43
pubmed: 18972444
Steroids. 2008 Apr;73(4):417-23
pubmed: 18243262
Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11
pubmed: 16410358
Gut. 2003 Oct;52(10):1494-9
pubmed: 12970144
J Steroid Biochem Mol Biol. 2019 May;189:218-227
pubmed: 30769091
Am J Pathol. 2009 Apr;174(4):1544-52
pubmed: 19286567
Biochim Biophys Acta. 2008 Apr;1778(4):1091-9
pubmed: 18177733
J Clin Endocrinol Metab. 1992 Mar;74(3):660-6
pubmed: 1740502
J Biol Chem. 2003 Aug 1;278(31):28765-70
pubmed: 12761213
Mol Endocrinol. 2003 Feb;17(2):259-72
pubmed: 12554753
Biochem J. 1993 Oct 15;295 ( Pt 2):329-41
pubmed: 8240230
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Diabetes Metab. 2008 Dec;34(6 Pt 2):685-91
pubmed: 19195631
Trends Mol Med. 2015 Nov;21(11):702-714
pubmed: 26481828
J Biol Chem. 2002 Mar 29;277(13):11019-25
pubmed: 11790787
Mol Endocrinol. 2006 Mar;20(3):686-97
pubmed: 16293642
Mol Cell. 1999 May;3(5):543-53
pubmed: 10360171
World J Gastroenterol. 2014 Oct 21;20(39):14430-41
pubmed: 25339829
Gastroenterology. 2013 Nov;145(5):1076-87
pubmed: 23916847
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89
pubmed: 26405614
PLoS One. 2016 May 20;11(5):e0151829
pubmed: 27203081
Gastroenterology. 2014 Mar;146(3):726-35
pubmed: 24316260
J Clin Invest. 2009 Feb;119(2):315-22
pubmed: 19164855
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Genome Res. 2012 Sep;22(9):1760-74
pubmed: 22955987
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Genes Dev. 2000 Nov 15;14(22):2819-30
pubmed: 11090130
J Clin Invest. 2004 May;113(10):1408-18
pubmed: 15146238
J Biol Chem. 2004 Mar 5;279(10):8856-61
pubmed: 14684751
Steroids. 2014 May;83:17-26
pubmed: 24513054
Diabetologia. 1997 Apr;40(4):463-8
pubmed: 9112024
Am J Dig Dis. 1975 Dec;20(12):1142-70
pubmed: 1200009
J Biol Chem. 2010 Aug 6;285(32):24529-37
pubmed: 20522910
Mol Cell Endocrinol. 2018 Jul 15;470:127-141
pubmed: 29024782
Endocrinology. 2013 Dec;154(12):4536-47
pubmed: 24080367
Pharm Res. 2013 May;30(5):1447-57
pubmed: 23371517
Genes Dev. 2000 Nov 15;14(22):2831-8
pubmed: 11090131
FEBS Lett. 2005 Aug 1;579(19):4076-80
pubmed: 16023103
Lancet. 2015 Mar 14;385(9972):956-65
pubmed: 25468160
Diabetes Metab. 2003 Nov;29(5):478-85
pubmed: 14631324
Cell Tissue Bank. 2017 Dec;18(4):597-604
pubmed: 28717878

Auteurs

Nikolaos Nikolaou (N)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Laura L Gathercole (LL)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Department of Biological and Medical Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.

Lea Marchand (L)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Sara Althari (S)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Niall J Dempster (NJ)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Charlotte J Green (CJ)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Martijn van de Bunt (M)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Catriona McNeil (C)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Anastasia Arvaniti (A)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK; Department of Biological and Medical Sciences, Oxford Brookes University, Oxford OX3 0BP, UK.

Beverly A Hughes (BA)

Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Bruno Sgromo (B)

Department of Upper GI Surgery, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Richard S Gillies (RS)

Department of Upper GI Surgery, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Hanns-Ulrich Marschall (HU)

Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden.

Trevor M Penning (TM)

Department of Systems Pharmacology & Translational Therapeutics, University of Pennsylvania Perelman School of Medicine, 1315 BRB II/III 421 Curie Blvd, Philadelphia, PA 19104-6160, United States of America.

John Ryan (J)

Translational Gastroenterology Unit, University of Oxford, Oxford, UK.

Wiebke Arlt (W)

Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Leanne Hodson (L)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK.

Jeremy W Tomlinson (JW)

Oxford Centre for Diabetes, Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, University of Oxford, Churchill Hospital, Oxford OX3 7LE, UK. Electronic address: jeremy.tomlinson@ocdem.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH